Trindade Guilherme G, Caxito Samyra M C, Xavier Alessandra Rejane E O, Xavier Mauro A S, BrandÃo Fabiana
University of Brasília, Laboratory of Clinical Microbiology and Immunology, Campus Darcy Ribeiro, Asa Norte, 70910-900 Brasília, DF, Brazil.
AMIL/United Health Group (UHG), 6580, SMAS Trecho 1, Guará, 70211-970 Brasília, DF, Brazil.
An Acad Bras Cienc. 2020 Jun 15;92(2):e20200466. doi: 10.1590/0001-3765202020200466. eCollection 2020.
COVID-19 emerged in December 2019 in China, and since then, has disrupted global public health and changed economic paradigms. In dealing with the new Coronavirus, SARS-CoV-2, the world has not faced such extreme global fragility since the "Spanish flu" pandemic in 1918. Researchers globally are dedicating efforts to the search for an effective treatment for COVID-19. Drugs already used in a clinical setting for other pathologies have been tested as a new therapeutic approach against SARS-CoV-2, setting off a frenzy over the preliminary data of different studies. This work aims to compile and discuss the data published thus far. Despite the potential effects of some antivirals and antiparasitic against COVID-19, clinical studies must confirm real effectiveness. However, non-pharmacological approaches have proven to be the most efficient strategy to date.
An Acad Bras Cienc. 2020-6-15
Biosci Trends. 2020-4-5
Antivir Chem Chemother. 2020
Curr Org Synth. 2020
Proc Natl Acad Sci U S A. 2020-5-19
Pharmaceuticals (Basel). 2021-11-8